Compare MAN & GENB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MAN | GENB |
|---|---|---|
| Founded | 1948 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Professional Services | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.7B |
| IPO Year | 1994 | N/A |
| Metric | MAN | GENB |
|---|---|---|
| Price | $30.40 | $13.32 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 6 | 6 |
| Target Price | ★ $35.67 | $23.20 |
| AVG Volume (30 Days) | ★ 1.2M | 315.7K |
| Earning Date | 04-16-2026 | 05-11-2026 |
| Dividend Yield | ★ 4.89% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $17,957,100,000.00 | N/A |
| Revenue This Year | $5.12 | N/A |
| Revenue Next Year | $3.42 | $16.58 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 0.58 | N/A |
| 52 Week Low | $25.15 | $11.00 |
| 52 Week High | $47.34 | $14.21 |
| Indicator | MAN | GENB |
|---|---|---|
| Relative Strength Index (RSI) | 54.35 | 55.60 |
| Support Level | $28.76 | $11.39 |
| Resistance Level | $30.40 | $13.40 |
| Average True Range (ATR) | 1.91 | 0.68 |
| MACD | 0.02 | 0.08 |
| Stochastic Oscillator | 60.43 | 85.96 |
ManpowerGroup Inc provides workforce solutions and services, including recruitment and assessment, upskilling, reskilling, training and development, career management, outsourcing, and workforce consulting. The company leverages its trusted brands, industry knowledge, and AI-enabled assessments and offers an extensive portfolio of training and leadership development solutions. Its reportable segments are Staffing and Interim, Outcome-Based Solutions and Consulting, Permanent Recruitment, and Others, with Staffing and Interim generating the majority of revenue. It operates in the Americas, Southern Europe, Northern Europe, and APME. The company derives the maximum geographical revenue from the Southern European region.
Generate Biomedicines Inc is a clinical-stage generative biology company pioneering the AI revolution in biotechnology and drug design and development. The company's single operating segment is engaged in the field of generative biology by using machine learning for drug discovery and development through the programming of novel protein therapeutics. Its product candidates include: GB-0895, GB-4362, and GB-5267. Through the company's Generate Platform, it can generate medicines on demand across multiple therapeutic modalities with unprecedented speed representing a fundamental shift in drug discovery.